Cargando…
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
AIM: Chemotherapy-induced toxicity is an independent prognostic indicator in several cancers. We aimed to determine whether toxicity was related to survival and histological response in high-grade localised extremity osteosarcoma. We undertook a retrospective analysis of patients treated within thre...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657154/ https://www.ncbi.nlm.nih.gov/pubmed/22036088 http://dx.doi.org/10.1016/j.ejca.2011.09.012 |
_version_ | 1782270101353922560 |
---|---|
author | McTiernan, Anne Jinks, Rachel C. Sydes, Matthew R. Uscinska, Barbara Hook, Jane M. van Glabbeke, Martine Bramwell, Vivien Lewis, Ian J. Taminiau, Antonie H.M. Nooij, Marianne A. Hogendoorn, Pancras C.W. Gelderblom, Hans Whelan, Jeremy S. |
author_facet | McTiernan, Anne Jinks, Rachel C. Sydes, Matthew R. Uscinska, Barbara Hook, Jane M. van Glabbeke, Martine Bramwell, Vivien Lewis, Ian J. Taminiau, Antonie H.M. Nooij, Marianne A. Hogendoorn, Pancras C.W. Gelderblom, Hans Whelan, Jeremy S. |
author_sort | McTiernan, Anne |
collection | PubMed |
description | AIM: Chemotherapy-induced toxicity is an independent prognostic indicator in several cancers. We aimed to determine whether toxicity was related to survival and histological response in high-grade localised extremity osteosarcoma. We undertook a retrospective analysis of patients treated within three consecutive randomised controlled trials (RCTs) of the European Osteosarcoma Intergroup. METHODS: Between 1982 and 2002, 533 patients were randomised to six cycles of doxorubicin 75 mg/m(2) and cisplatin 100 mg/m(2). Toxicity data were collected prospectively and graded according to the World Health Organisation (WHO) criteria. Standard univariate and multivariate models were constructed to examine the relationship between reported toxicity, survival, and histological response. RESULTS: Five- and 10-year overall survival was 57% (95% confidence interval (CI) 52–61%) and 53% (49–58%), respectively. Grades 3–4 oral mucositis (hazard ratio (HR) 0.51, 95% CI 0.29–0.91), grades 1–2 nausea/vomiting (HR 0.37, 95% CI 0.16–0.85), grades 1–2 thrombocytopenia (HR 0.49, 95% CI 0.27–0.87), good histological response (HR 0.42, 95% CI 0.27–0.65), and distal tumour site (HR 0.45, 95% CI 0.28–0.71) were associated with improved survival in multivariate analysis. The only factors that were independently associated with histological response were older age (odds ratio (OR) 0.18, 95% CI 0.04–0.72) and chondroblastic tumour (OR 0.28, 95% CI 0.10–0.77), both being associated with a significantly lower chance of achieving a good response. CONCLUSION: Chemotherapy-induced toxicity predicts survival in patients with localised extremity osteosarcoma. Investigation of the pharmacogenomic mechanisms of constitutional chemosensitivity underlying these observations will present opportunities for personalising treatment and could lead to improved outcomes. |
format | Online Article Text |
id | pubmed-3657154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Elsevier Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36571542013-05-18 Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup McTiernan, Anne Jinks, Rachel C. Sydes, Matthew R. Uscinska, Barbara Hook, Jane M. van Glabbeke, Martine Bramwell, Vivien Lewis, Ian J. Taminiau, Antonie H.M. Nooij, Marianne A. Hogendoorn, Pancras C.W. Gelderblom, Hans Whelan, Jeremy S. Eur J Cancer Article AIM: Chemotherapy-induced toxicity is an independent prognostic indicator in several cancers. We aimed to determine whether toxicity was related to survival and histological response in high-grade localised extremity osteosarcoma. We undertook a retrospective analysis of patients treated within three consecutive randomised controlled trials (RCTs) of the European Osteosarcoma Intergroup. METHODS: Between 1982 and 2002, 533 patients were randomised to six cycles of doxorubicin 75 mg/m(2) and cisplatin 100 mg/m(2). Toxicity data were collected prospectively and graded according to the World Health Organisation (WHO) criteria. Standard univariate and multivariate models were constructed to examine the relationship between reported toxicity, survival, and histological response. RESULTS: Five- and 10-year overall survival was 57% (95% confidence interval (CI) 52–61%) and 53% (49–58%), respectively. Grades 3–4 oral mucositis (hazard ratio (HR) 0.51, 95% CI 0.29–0.91), grades 1–2 nausea/vomiting (HR 0.37, 95% CI 0.16–0.85), grades 1–2 thrombocytopenia (HR 0.49, 95% CI 0.27–0.87), good histological response (HR 0.42, 95% CI 0.27–0.65), and distal tumour site (HR 0.45, 95% CI 0.28–0.71) were associated with improved survival in multivariate analysis. The only factors that were independently associated with histological response were older age (odds ratio (OR) 0.18, 95% CI 0.04–0.72) and chondroblastic tumour (OR 0.28, 95% CI 0.10–0.77), both being associated with a significantly lower chance of achieving a good response. CONCLUSION: Chemotherapy-induced toxicity predicts survival in patients with localised extremity osteosarcoma. Investigation of the pharmacogenomic mechanisms of constitutional chemosensitivity underlying these observations will present opportunities for personalising treatment and could lead to improved outcomes. Elsevier Science Ltd 2012-03 /pmc/articles/PMC3657154/ /pubmed/22036088 http://dx.doi.org/10.1016/j.ejca.2011.09.012 Text en © 2012 Elsevier Ltd. https://creativecommons.org/licenses/by/3.0/ Open Access under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) license |
spellingShingle | Article McTiernan, Anne Jinks, Rachel C. Sydes, Matthew R. Uscinska, Barbara Hook, Jane M. van Glabbeke, Martine Bramwell, Vivien Lewis, Ian J. Taminiau, Antonie H.M. Nooij, Marianne A. Hogendoorn, Pancras C.W. Gelderblom, Hans Whelan, Jeremy S. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup |
title | Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup |
title_full | Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup |
title_fullStr | Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup |
title_full_unstemmed | Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup |
title_short | Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup |
title_sort | presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the european osteosarcoma intergroup |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657154/ https://www.ncbi.nlm.nih.gov/pubmed/22036088 http://dx.doi.org/10.1016/j.ejca.2011.09.012 |
work_keys_str_mv | AT mctiernananne presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT jinksrachelc presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT sydesmatthewr presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT uscinskabarbara presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT hookjanem presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT vanglabbekemartine presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT bramwellvivien presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT lewisianj presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT taminiauantoniehm presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT nooijmariannea presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT hogendoornpancrascw presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT gelderblomhans presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup AT whelanjeremys presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup |